Karen R. Jacobson, MD, MPH
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Infectious Diseases

MD, Johns Hopkins University School of Medicine
MPH, Harvard School of Public Health

Dr. Karen Jacobson is an Assistant Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of drug resistant tuberculosis, including identification of social, biological, and economic determinants of and risk factors for drug resistance and approaches for improving TB outcomes in resource-limited settings. Dr. Jacobson has established a highly productive collaboration with researchers at Stellenbosch University in Cape Town, South Africa, investigating the drivers of drug resistance in the Western Cape Province of South Africa and working to identify potentially modifiable factors.

Assistant Professor
Boston University School of Public Health

The impact of alcohol consumption on TB treatment outcomes
04/08/2016 - 03/31/2021 (PI)

URBAN ARCH (3/5) Uganda Cohort- TB prevention therapy for HIV-infected alcohol drinkers in Uganda…
09/22/2016 - 08/31/2018 (PI)
The Regents of the University of California NIH-NIAAA

ASTMH Fellowship in Tropical Infectious Diseases
02/01/2013 - 06/30/2018 (PI)
American Society of Tropical Medicine and Hygiene

Phase 2 Pharmacodynamic Study of Hidh-dose Levofloxacin in MDR-TB Treatment
01/01/2015 - 07/31/2017 (PI)
Trustees of Boston University NIH-NIAID

Geospatial clustering and molecular and social epidemiology of drug resistant TB
08/01/2013 - 12/31/2016 (PI)

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Morgan Freiman J, Jacobson KR, Muyindike WR, Robert Horsburgh C, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People with HIV who are Heavy Alcohol Drinkers in High TB/HIV Burden Countries: a Risk-Benefit Analysis. J Acquir Immune Defic Syndr. 2017 Dec 06.View Related Profiles. PMID: 29239900.
  2. Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15; 65(8):1364-1370. PMID: 29017248.
  3. Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF, Shapira O, Dolby T, Simpson J, Scott L, Stevens W, van Helden PD, Van Rie A, Warren RM. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clin Infect Dis. 2017 Jun 01; 64(11):1502-1508.View Related Profiles. PMID: 28199520; DOI: 10.1093/cid/cix128;.
  4. Jacobson KR. Tuberculosis. Ann Intern Med. 2017 Feb 07; 166(3):ITC17-ITC32. PMID: 28166561; DOI: 10.7326/AITC201702070;.
  5. Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med. 2016 Sep 01; 194(5):621-30.View Related Profiles. PMID: 26910495; PMCID: PMC5027209; DOI: 10.1164/rccm.201510-2091OC;.
  6. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016 Mar; 54(3):727-33. PMID: 26763957; PMCID: PMC4767988; DOI: 10.1128/JCM.02775-15;.
  7. Jacobson KR, Sabin LL. Scaling up multidrug-resistant tuberculosis care in China. Lancet Glob Health. 2015 Apr; 3(4):e183-4.View Related Profiles. PMID: 25794667; PMCID: PMC4492310; DOI: 10.1016/S2214-109X(15)70093-8;.
  8. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41. PMID: 25686144; PMCID: PMC4486051; DOI: 10.5588/ijtld.14.0814;.
  9. Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, Warren RM, Jacobson KR. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. PLoS One. 2013; 8(12):e83480. PMID: 24349518; PMCID: PMC3862731; DOI: 10.1371/journal.pone.0083480;.
  10. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014 Feb; 69(2):331-42. PMID: 24055765; PMCID: PMC3886931; DOI: 10.1093/jac/dkt358;.
Showing 10 of 18 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 18 publications over 9 distinct years, with a maximum of 4 publications in 2017

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

drug resistant tuberculosis
global health
spatial mapping
Contact for Mentoring:

771 Albany St
Boston MA 02118
Google Map

Jacobson's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department